New York, USA, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Duchenne Muscular Dystrophy Market to Propel at a Significant CAGR by 2032, Assesses DelveInsight | Key Companies - Pfizer, Santhera, Taiho, FibroGen, Sarepta, Capricor, Daiichi Sankyo, Solid Biosciences
Duchenne muscular dystrophy market dynamics are anticipated to change in the coming years owing to the improvement in the research and development activities for efficient treatment options to be available in the DMD market.
DelveInsight’s Duchenne Muscular Dystrophy Market Insights report includes a comprehensive understanding of current treatment practices, Duchenne muscular dystrophy emerging drugs, market share of individual therapies, and current and forecasted Duchenne muscular dystrophy market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
Key Takeaways from the Duchenne Muscular Dystrophy Market Report
- As per DelveInsight’s analysis, the Duchenne muscular dystrophy market size was found to be USD 1.7 billion in 2022 in the 7MM and it is anticipated to grow at a significant CAGR by 2032.
- As per DelveInsight estimates, the total prevalent cases of DMD in the seven major markets are estimated to be around 34K in 2032
- Leading Duchenne muscular dystrophy companies such as Pfizer, Santhera Pharmaceuticals, ReveraGen BioPharma, Taiho Pharmaceutical, FibroGen, Sarepta Therapeutics, Capricor Therapeutics, Daiichi Sankyo, Italfarmaco, Antisense Therapeutics, Solid Biosciences, and others are developing novel Duchenne muscular dystrophy drugs that can be available in the Duchenne muscular dystrophy market in the coming years.
- Some of the key therapies for Duchenne muscular dystrophy treatment include PF-06939926, Vamorolone, Pizuglanstat (TAS-205), Pamrevlumab (FG-3019), SRP-9001, Allogeneic Cardiosphere-derived Cells (CAP-1002), DS-5141b, Givinostat, ATL1102, SRP-5051, SGT-001, and others.
Discover which therapies are expected to grab the major Duchenne muscular dystrophy market share @ Duchenne Muscular Dystrophy Market Report
Duchenne Muscular Dystrophy Overview
Duchenne muscular dystrophy (DMD) stands as the most prevalent type of muscular dystrophy affecting children. It is an inherited condition characterized by a gradual breakdown of muscle tissue and weakness. DMD falls under the category of nine distinct types of muscular dystrophy. DMD arises due to the absence of dystrophin, a critical protein that plays a role in maintaining the integrity of muscle cells. The first signs of this condition typically manifest in early childhood, usually between the ages of 3 and 5.
Key clinical features of DMD include progressive muscle weakness and atrophy in various voluntary muscles throughout the body. In its advanced stages, the heart and digestive muscles can also be impacted. Symptoms typically become noticeable in boys aged 1 to 6 years. Muscle strength progressively declines between the ages of 6 and 11. By the age of 10, some individuals may require leg braces for walking, and by the age of 13, most boys with DMD rely on a wheelchair for mobility.
Duchenne Muscular Dystrophy Epidemiology Segmentation
The Duchenne muscular dystrophy epidemiology section provides insights into the historical and current Duchenne muscular dystrophy patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.
The DMD market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total DMD Prevalent Population
- DMD Age-specific Prevalent Population
- DMD Ambulatory and Non-ambulatory Population
- DMD Mutation-specific Prevalent Population
- Associated Comorbidities in Duchenne Muscular Dystrophy
Download the report to understand which factors are driving Duchenne muscular dystrophy epidemiology trends @ Duchenne Muscular Dystrophy Epidemiological Insights
Duchenne Muscular Dystrophy Market
While there is currently no cure for any type of muscular dystrophy, there are treatment options available for certain forms of the condition, such as DMD. These treatments aim to prolong mobility and improve heart and lung muscle strength. Key therapeutic approaches for managing DMD include gene replacement or other genetic therapies tailored to specific mutations to restore dystrophin production, as well as strategies focused on membrane stabilization, enhancement of compensatory protein levels, and reducing inflammation to support muscle regeneration.
Additionally, there are several guidelines for diagnosing and managing Duchenne muscular dystrophy (DMD). These guidelines recommend the use of corticosteroids, which have been shown to benefit boys with DMD by stabilizing muscle strength, prolonging independent ambulation, and delaying the progression of scoliosis and cardiomyopathy. In the United States, there are approved products available, including EMFLAZA (deflazacort), VYONDYS 53 (golodirsen), EXONDYS 51 (eteplirsen), AMONDYS 45 (casimersen), and VILTEPSO (viltolarsen) for DMD patients. In the European Union and the United Kingdom, steroid therapies are commonly used, along with TRANSLARNA (ataluren), which is approved for DMD patients with nonsense mutation. In Japan, the only approved treatment is VILTEPSO (viltolarsen).
Sarepta Therapeutics stands out among the prominent market players, boasting three approved assets currently in circulation and an additional two in the development pipeline for DMD. Nevertheless, competition is on the rise. Examining the historical trajectory of DMD, the likelihood of market entry varies across the 7MM. Remarkably, the DMD market exhibits significant geographical disparities in terms of regulatory approval, with instances of products gaining approval in one jurisdiction while facing rejection in another despite presenting identical clinical data.
Learn more about the FDA-approved drugs for DMD @ Drugs for Duchenne Muscular Dystrophy Treatment
Key Duchenne Muscular Dystrophy Therapies and Companies
- PF-06939926: Pfizer
- Vamorolone: Santhera Pharmaceuticals/ReveraGen BioPharma
- Pizuglanstat (TAS-205): Taiho Pharmaceutical
- Pamrevlumab (FG-3019): FibroGen
- SRP-9001: Sarepta Therapeutics
- Allogeneic Cardiosphere-derived Cells (CAP-1002): Capricor Therapeutics
- DS-5141b: Daiichi Sankyo
- Givinostat: Italfarmaco
- ATL1102: Antisense Therapeutics
- SRP-5051: Sarepta Therapeutics
- SGT-001: Solid Biosciences
To know more about Duchenne muscular dystrophy clinical trials, visit @ DMD Treatment Drugs
Duchenne Muscular Dystrophy Market Dynamics
The landscape of the DMD market is poised to undergo significant changes in the near future due to advancements in research and development efforts aimed at providing more effective treatment options. The DMD pipeline is robust, with numerous potential products in the advanced stages of clinical development. Notably, several new therapies for DMD treatment have gained recent approvals, including VILTEPSO’s launch in Japan. Therapies like Capricor’s CAP-1002 and Antisense’s ATL1102 are now poised for broader commercial opportunities. These therapies specifically target the improvement of upper limb functions in DMD patients and cater to a much larger patient population compared to exon-skipping therapies.
However, certain factors will impede the DMD market growth in the coming years. Glucocorticosteroids, the traditional go-to treatment, come with a range of undesirable side effects. Conversely, newer corticosteroids like EMFLAZA are not economically viable in the United States. Unfortunately, there is currently no cure or therapy to reverse the disease for nonambulant DMD patients. Additionally, the high cost of upcoming therapies presents a major challenge. The limited availability of participants for trial recruitment is a significant hurdle as well. Moreover, due to DMD’s rarity among pediatric diseases, clinical trials struggle to enroll a sufficient number of participants compared to more prevalent conditions.
| Duchenne Muscular Dystrophy Report Metrics | Details |
| Study Period | 2019–2032 |
| Duchenne Muscular Dystrophy Report Coverage | 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] |
| Duchenne Muscular Dystrophy Market Size in 2022 | USD 1.7 Billion |
| Key Duchenne Muscular Dystrophy Companies | Pfizer, Santhera Pharmaceuticals, ReveraGen BioPharma, Taiho Pharmaceutical, FibroGen, Sarepta Therapeutics, Capricor Therapeutics, Daiichi Sankyo, Italfarmaco, Antisense Therapeutics, Solid Biosciences, and others |
| Key Duchenne Muscular Dystrophy Therapies | PF-06939926, Vamorolone, Pizuglanstat (TAS-205), Pamrevlumab (FG-3019), SRP-9001, Allogeneic Cardiosphere-derived Cells (CAP-1002), DS-5141b, Givinostat, ATL1102, SRP-5051, SGT-001, and others |
Scope of the Duchenne Muscular Dystrophy Market Report
- Therapeutic Assessment: Duchenne Muscular Dystrophy current marketed and emerging therapies
- Duchenne Muscular Dystrophy Market Dynamics: Attribute Analysis of Emerging Duchenne Muscular Dystrophy Drugs
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, Duchenne Muscular Dystrophy Market Access and Reimbursement
Discover more about DMD drugs in development @ Duchenne Muscular Dystrophy Clinical Trials
Table of Contents
| 1. | Duchenne Muscular Dystrophy Market Key Insights |
| 2. | Duchenne Muscular Dystrophy Market Report Introduction |
| 3. | Duchenne Muscular Dystrophy Market Overview at a Glance |
| 4. | Duchenne Muscular Dystrophy Market Executive Summary |
| 5. | Disease Background and Overview |
| 6. | Duchenne Muscular Dystrophy Treatment and Management |
| 7. | Duchenne Muscular Dystrophy Epidemiology and Patient Population |
| 8. | Patient Journey |
| 9. | Duchenne Muscular Dystrophy Marketed Drugs |
| 10. | Duchenne Muscular Dystrophy Emerging Drugs |
| 11. | Seven Major Duchenne Muscular Dystrophy Market Analysis |
| 12. | Duchenne Muscular Dystrophy Market Outlook |
| 13. | Potential of Current and Emerging Therapies |
| 14. | KOL Views |
| 15. | Unmet Needs |
| 16. | SWOT Analysis |
| 17. | Appendix |
| 18. | DelveInsight Capabilities |
| 19. | Disclaimer |
| 20. | About DelveInsight |
Related Reports
Duchenne Muscular Dystrophy Epidemiology Forecast
Duchenne Muscular Dystrophy Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted Duchenne muscular dystrophy epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Duchenne Muscular Dystrophy Pipeline
Duchenne Muscular Dystrophy Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Duchenne muscular dystrophy companies, including Santhera Pharmaceuticals, Sarepta Therapeutics, Italfarmaco, Wave Life Sciences Ltd, FibroGen, Edgewise Therapeutics, Pfizer, Daiichi Sankyo, Sarepta Therapeutics, Inc., ENCell, Taiho Pharmaceutical, Solid Biosciences, Capricor, Nippon Shinyaku, Hansa Biopharma, Ultragenyx Pharmaceutical, Dyne Therapeutics, Entrada Therapeutics, AAVogen, PepGen, Antisense Therapeutics, BioMarin Pharmaceutical, Avidity Biosciences, Sarepta Therapeutics, Dyne Therapeutics, Solid Biosciences Inc, Regenxbio, Stealth BioTherapeutics, among others.
Nonsense Mutation Duchenne Muscular Dystrophy Pipeline
Nonsense Mutation Duchenne Muscular Dystrophy Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key nonsense mutation Duchenne muscular dystrophy companies, including Taiho Pharmaceutical, Solid Biosciences, Capricor, Nippon Shinyaku, among others.
Becker Muscular Dystrophy Pipeline
Becker Muscular Dystrophy Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key becker muscular dystrophy companies, including Epirium Bio, Ultragenyx, Strykagen, among others.
Facioscapulohumeral Muscular Dystrophy PIpeline
Facioscapulohumeral Muscular Dystrophy Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key facioscapulohumeral muscular dystrophy companies, including miRecule, Arrowhead Pharmaceuticals, Fulcrum Therapeutics, among others.
Other Trending Reports
Digestive System Fistula Market | Dementia With Diabetes Market | Leber's Hereditary Optic Neuropathy Market | Pecoma Market | Adamantinoma Market | Pegfilgrastim Biosimilar Insight | Functional Constipation Market | DDR Defective Tumors Market | Nephrotic Syndrome Pipeline | Pelizaeus-Merzbacher Disease Market | Hepatic Impairment Market | Primary Ciliary Dyskinesia Market | Surgical Bleeding Market | Radiotherapy-Induced Oral Mucositis Market | Relapsed Chronic Lymphocytic Leukemia CLL Market | Galactosemia Market | Glabellar Lines Market | Homozygous Familial Hypercholesterolemia Market | HR Positive/ HER2 Negative Breast Cancer Market | Lebers Hereditary Optic Neuropathy LHON Market | Nonalcoholic Fatty Liver Disease NAFLD Market | Orthotic Devices Market | Polypoidal Choroidal Vasculopathy Market | Sporadic Inclusion Body Myositis Market | Warm Autoimmune Hemolytic Anemia Market | Acid Sphingomyelinase Deficiency ASMD Market | B-Cell Chronic Lymphocytic Leukemia Market | Coccidioidomycosis Market | Frontotemporal Dementia Pipeline | Granulomatosis With Polyangiitis Market | Malignant Pleural Mesothelioma Market | Nocturnal Enuresis Market | Postmyocardial Infarction Syndrome Market | Severe Acute Respiratory Syndrome Sars Coronavirus Infection Market | Typhoid Fever Market | Ventricular Dysfunction Market | Burkitt Lymphoma Market | Chronic Progressive Multiple Sclerosis Market | Emesis Market | Fenebrutinib Market | Gastric Neuroendocrine Tumors Market | Juvenile Rheumatoid Arthritis Market | Persistent Epithelial Defects Market | Post-Polycythemia Vera Myelofibrosis Market | Primary Mediastinal Large B-Cell Lymphoma Market | Spinocerebellar Ataxias Market | Systemic Inflammatory Response Syndrome Market | Triple Negative Breast Cancer Market | Visceral Pain Associated With GI Disorders Market | Adrenal Cortex Neoplasms Market | Adrenal Insufficiency Market | Artificial Lung Devices Market | Atopic Keratoconjunctivitis AKC Market | Autonomic Dysfunction Market | Bradycardia Treatment Devices Market | Bullous Pemphigoid Market | Cone Rod Dystrophy Market | Cutaneous Lupus Erythematosus Market | Cyclin-Dependent Kinase-Like 5 Deficiency Disorder Market | Dermal Regeneration Matrix Market | Heart Pump Devices Market | Hemiplegia Market | Hepatic Impairement Market | Immunologic Deficiency Syndrome Market | Implantable Infusion Pump Market | Menorrhalgia Market Size | Myocarditis Market | Myopia Treatment Devices Market | Ocular Hypertension Market
Related Healthcare Services
Healthcare Competitive Intelligence Services
Healthcare Asset Prioritization Services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect with us on LinkedIn|Facebook|Twitter
